EFPIA - NEWSLETTER

EFPIA Newsletter 09 November 2023

How would the proposed EU Pharma Legislation affect Europe's competitiveness?

A study from Dolon, commissioned by EFPIA, shows that the Commission’s plans could accelerate Europe's decline in innovation compared to the USA, China, and Japan. This could result in:

A one-third reduction in Europe's share of global R&D investment by 2040, dropping from 32% to 21%.
Loss of one in five medicines in development (22%) which would no longer be economically viable in Europe.
A loss of 16 million years of life lost (YLL) due to increased mortality and premature death across the EU.

Regaining lost ground: It’s time for a future-oriented pharmaceutical policy

"Europe must take back its leadership and develop a long-term strategy and policies to regain, sustain, and develop life sciences in Europe."

Check out what Peter Guenter, CEO of Healthcare at Merck, has written on POLITICO.

Blogs

07 November 2023 Improving men's health standards in Europe: a vital need for action (Guest blog)

As #Movember kicks off, we turn to two experts from the Let’s Talk Prostate Cancer (LTPC) Expert Group to shed light...

Listen to Christian Schneider on how an improved regulatory environment could benefit competitiveness

In this podcast, we discuss the continuing challenges to Europe’s Biopharma competitiveness, and how an improved regulatory environment could be a benefit. Christian also highlights both the risks and opportunities of the EU’s proposed revision of the general pharmaceutical legislation.

This podcast was developed in collaboration with Vital Transformation.

It's #MedSafetyWeek!

Join the discussion to help us spread the word about reporting side effects.

What we are reading

Patient involvement in HTA in Europe 01 November 2023 (HTAi)

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective 02 November 2023 (OHE)

RADIAL has recruited its first remote patient 03 November 2023 (Trials@Home)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶